Published in Med Care on April 01, 2013
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012) 15.83
Evidence on screening for breast cancer from a randomized trial. Cancer (1977) 7.91
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 6.99
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA (2000) 1.89
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control (2012) 1.36
An analysis of the mortality effect in a breast cancer screening study. Int J Epidemiol (1986) 1.15
A likelihood ratio test for cancer screening trials. Biometrics (1995) 1.04
Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 0.94
The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context. Acta Oncol (2011) 0.92
Measuring mortality reductions in cancer screening trials. Epidemiol Rev (2011) 0.91
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med (2013) 1.84
Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int (2011) 1.48
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol (2013) 1.41
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos. Am J Clin Nutr (2010) 1.17
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol (2013) 1.14
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol (2010) 1.12
Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One (2013) 1.03
Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs (2010) 0.97
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate (2010) 0.96
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst (2013) 0.95
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol (2012) 0.95
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
RE: A model too far. J Natl Cancer Inst (2014) 0.93
Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol (2013) 0.89
Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev (2009) 0.86
Oversimplifying overdiagnosis. J Gen Intern Med (2014) 0.82
Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. Am J Epidemiol (2016) 0.75
Alternative prostate cancer screening strategies--in response. Ann Intern Med (2013) 0.75